650 completed, 280 terminated, 184 recruiting, 160 unknown. 1527 Phase 2, 395 Phase 1, 52 Phase 3.
Follow Neoplasm Metastasis: new trials by email Literature Review of Neoplasm Metastasis trials Research Report on Neoplasm Metastasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN) SRS/fSRT+T-Dxd - Breast Cancer (Advanced/Metastatic) | Phase 2 | Not yet recruiting | Azienda Ospedaliero-Universitaria Careggi | 60 | 2027-05-15 | 2026-10-29 |
| Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor) | Phase 2 | Not yet recruiting | Girish Dhall, MD | 25 | 2027-01-01 | 2026-10-28 |
| Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 40 | 2026-12-31 | 2026-10-28 |
| Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab - Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm | Phase 2 | Not yet recruiting | VA Office of Research and Development | 30 | 2026-12-01 | 2026-10-06 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Real-world Trial of Individualized Precision Oncology Molecularly matched therapy, Standard of care - Metastatic Cancer, Unresectable Carcinoma | Phase 2 | Not yet recruiting | University of California, San Diego | 280 | 2026-12-01 | 2026-09-03 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp Dexamethasone - Uveal Melanoma, Metastatic | Phase 2 | Not yet recruiting | University of California, San Diego | 34 | 2026-11-01 | 2026-09-03 |
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-08-28 |
| Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva Tisotumab Vedotin - Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer | Phase 2 | Not yet recruiting | GOG Foundation | 28 | 2026-11-01 | 2026-06-29 |
| Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers Trastuzumab Deruxtecan - HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2 | Phase 2 | Not yet recruiting | University of Chicago | 43 | 2026-11-01 | 2026-01-08 |
| Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP) Sacituzumab Tirumotecan - Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic | Phase 2 | Not yet recruiting | National Cancer Centre, Singapore | 68 | 2026-11-01 | 2026-07-15 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma 64Cu-DOTA-ECL1i - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 2 | Recruiting | Washington University School of Medicine | 90 | 2026-10-31 | 2026-10-07 |
| CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ | Phase 1 / Phase 2 | Recruiting | Crescent Biopharma, Inc. | 219 | 2026-10-21 | 2026-11-02 |
| Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases Primary Tumor Resection and Selective Lymph Node Dissection, Postoperative Radiotherapy, Capecitabine or S-1 - Biliary Tract Cancer (BTC), Surgery | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 73 | 2026-10-08 | 2026-10-26 |
| First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma mFOLFIRINOX versus FOLFOX chemotherapy - Small-bowel Adenocarcinoma, Metastatic Disease | Phase 2 | Not yet recruiting | Annika Kurreck | 86 | 2026-10-01 | 2026-09-28 |
Showing 20 of 1527. Sign in to see all of them.
Neoplasms (237) · Breast Neoplasms (226) · Colorectal Neoplasms (193) · Carcinoma, Non-Small-Cell Lung (142) · Melanoma (129) · Recurrence (125) · Prostatic Neoplasms (105) · Pancreatic Neoplasms (101) · Lung Neoplasms (96) · Carcinoma, Renal Cell (90) · Colonic Neoplasms (74) · Stomach Neoplasms (71) · Brain Neoplasms (62) · Squamous Cell Carcinoma of Head and Neck (61)
Pathological Conditions, Signs and Symptoms (1526) · Pathologic Processes (1523) · Neoplastic Processes (1522) · Neoplasms (1290) · Neoplasms by Site (1149) · Neoplasms by Histologic Type (507) · Digestive System Diseases (424) · Digestive System Neoplasms (418) · Skin and Connective Tissue Diseases (360) · Skin Diseases (359) · Neoplasms, Glandular and Epithelial (341) · Urogenital Diseases (310) · Gastrointestinal Diseases (307) · Urogenital Neoplasms (305) · Carcinoma (281)
Gemcitabine (93) · pembrolizumab (89) · Capecitabine (87) · Paclitaxel (79) · Oxaliplatin (78) · Bevacizumab (71) · Fluorouracil (71) · Nivolumab (64) · Carboplatin (57) · Leucovorin (57) · Cisplatin (56) · Docetaxel (55) · Irinotecan (51) · Cetuximab (50) · Cyclophosphamide (46)
M.D. Anderson Cancer Center (64) · National Cancer Institute (NCI) (48) · Memorial Sloan Kettering Cancer Center (25) · UNICANCER (19) · Amgen (18) · H. Lee Moffitt Cancer Center and Research Institute (17) · AstraZeneca (16) · Dana-Farber Cancer Institute (16) · Eli Lilly and Company (16) · Fudan University (13) · Novartis Pharmaceuticals (13) · University Health Network, Toronto (13) · Massachusetts General Hospital (12) · Duke University (11) · Pfizer (11)
United States (871) · France (213) · Spain (180) · China (125) · Italy (124) · Germany (119) · Canada (118) · United Kingdom (114) · South Korea (112) · Belgium (103) · Australia (101) · Netherlands (74) · Poland (59) · Taiwan (49) · Russia (40)
Steven A Rosenberg, M.D. (10) · Jonathan Strosberg, M.D. (5) · Marleen Kok, MD (5)
PMID 37146227, PMID 25303679, PMID 25789053, PMID 32306237, PMID 33084020, PMID 33138866, PMID 33270906, PMID 34213592, PMID 37597578, PMID 38421252, PMID 42186347, PMID 10091726, PMID 10493478, PMID 10555755, PMID 11123390, PMID 11813623, PMID 14673042, PMID 14963856, PMID 15042609, PMID 15215160, PMID 15313917, PMID 15681523, PMID 15755984, PMID 15908664, PMID 16009952, PMID 16172161, PMID 16172168, PMID 16230673, PMID 16314647, PMID 16344433, PMID 16622264, PMID 16859580, PMID 17016557, PMID 17050875, PMID 17418968, PMID 17470864, PMID 17543307, PMID 17554116, PMID 17647245, PMID 17671985, PMID 17704420, PMID 17785764, PMID 17876014, PMID 17987262, PMID 18008108, PMID 18077217, PMID 18268188, PMID 18316791, PMID 18316792, PMID 18334033
2023 (29), 2019 (18), 2016 (17), 2025 (16), 2014 (11), 2017 (11), 2008 (10), 2018 (9), 2009 (6), 2015 (6), P30CA016672 (6), U10CA032102 (6), 2005 (4), P30CA060553 (4), U10CA180820 (4)